Drug Profile
MEDI 5395
Alternative Names: MEDI-5395; Oncolytic Newcastle Disease VirusLatest Information Update: 03 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Advanced glycosylation end product modulators; Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
- No development reported Cancer
Most Recent Events
- 10 Sep 2023 Pharmacokinetics data from a phase I trial in Solid tumours presented at the 2023 American College of Clinical Pharmacology Annual Meeting (ACCP-2023)
- 03 Mar 2023 MEDI 5395 is still in phase I development in Solid-tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT03889275)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV)